A Single Blind, Placebo Controlled Study to Explore the Safety and Tolerability of a Single Oral Dose of 30 mg BAY1067197 in Patients With Chronic Heart Failure on the Background of Preexisting Beta-blocker Therapy

Trial Profile

A Single Blind, Placebo Controlled Study to Explore the Safety and Tolerability of a Single Oral Dose of 30 mg BAY1067197 in Patients With Chronic Heart Failure on the Background of Preexisting Beta-blocker Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2015

At a glance

  • Drugs BAY 1067197 (Primary)
  • Indications Heart failure
  • Focus Adverse reactions
  • Sponsors Bayer
  • Most Recent Events

    • 31 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 07 Dec 2014 Planned End Date changed from 1 Sep 2014 to 1 Dec 2014 as reported by ClinicalTrial.gov.
    • 07 Dec 2014 Status changed from completed to active, no longer recruiting as reported by ClinicalTrial.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top